Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey.
BACKGROUND
Chronic idiopathic (also called spontaneous) urticaria (CIU/CSU) is the most common form of chronic urticaria and has been associated with impairment to health outcomes, although the effect has never been assessed using a nationally representative sample in the United States.


OBJECTIVE
To assess the burden of CIU/CSU from the patients' perspective in terms of health related quality of life, impairment to work and nonwork activities, and health care resource use.


METHODS
Data were obtained from the US National Health and Wellness Survey. Current use of a prescription for the treatment of chronic hives was used as a proxy for CIU/CSU. Patients with CIU/CSU in the proxy group were matched 1:4 to respondents without chronic hives using survey year, sex, age, and race. Generalized linear models were adjusted for comorbidities, smoking, body mass index, and health insurance status. Outcome measures included the Medical Outcomes Study 12-Item and 36-Item Short Form Health Surveys; self-reported depression, anxiety, and sleep difficulties; the Work Productivity and Activity Impairment questionnaire, and health care resource use.


RESULTS
After matching and adjustment for covariates, those currently using a prescription for chronic hives had mental component summary scores 5.7 points lower, physical component summary scores 6.5 points lower, and health utility scores 0.11 points lower than controls, as well as higher adjusted odds of reporting depression, anxiety, and sleep difficulties. Mean adjusted work impairment was approximately double in prescription-treated chronic hives relative to controls, as was frequency of health care visits.


CONCLUSIONS
Chronic hives substantially affects quality of life, nonwork activities, capacity to work, and health care use, providing further evidence of a high burden of CIU/CSU across multiple health outcomes and unmet need for effective treatment.
Kantar Health, Health Outcomes Practice, Horsham, Pennsylvania. Electronic address: Jeffrey.vietri@kantarhealth.com.
Jeffrey
J
Vietri
Novartis Pharmaceutical Corporation, US Health Economics and Outcomes Research, East Hanover, New Jersey.
Stuart J
SJ
Turner
Novartis Pharmaceutical Corporation, Global Medical Affairs, East Hanover, New Jersey.
Haijun
H
Tian
Kantar Health, Health Outcomes Practice, Epsom, Surrey, United Kingdom.
Gina
G
Isherwood
Novartis Pharma AG, IHC, Basel, Switzerland.
Maria-Magdalena
MM
Balp
Novartis Pharmaceutical Corporation, US Health Economics and Outcomes Research, East Hanover, New Jersey.
Susan
S
Gabriel
D001007:Anxiety / Q000523:psychology; D015992:Body Mass Index; D002908:Chronic Disease; D015897:Comorbidity; D017281:Cost of Illness; D003430:Cross-Sectional Studies; D003863:Depression / Q000523:psychology; D005260:Female; D006306:Health Surveys; D006801:Humans; D007348:Insurance, Health / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011788:Quality of Life; D012189:Retrospective Studies; D012907:Smoking / Q000453:epidemiology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014481:United States; D014581:Urticaria / Q000188:drug therapy / Q000453:epidemiology* / Q000523:psychology*